Cat. No.: HY-N0174

Cryptotanshinone

(Synonyms: Cryptotanshinon; Tanshinone c)

47 Cited Publications

고객리뷰

Based on 47 publication(s) in Google Scholar

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC₅₀ of 4.6 μM.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.07%
CAS No.: 35825-57-1
화학식: C₁₉H₂₀O₃
분자량:296.36

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Cryptotanshinone Chemical Structure

CAS No.: 35825-57-1

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (47)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Bioz

Biological Activity

제품 설명

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits STAT3 with an IC₅₀ of 4.6 μM.

IC₅₀ & Target^[1]

STAT3

4.6 μM (IC₅₀)

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	1.58 μM Compound: 3, cryptotanshinone	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	10.2 μM Compound: 3, cryptotanshinone	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	13.5 μM Compound: 3, cryptotanshinone	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
BaF3	IC₅₀	17.22 μM Compound: Cryptotanshinone	Growth inhibition of IL3-stimulated mouse BA/F3 cells after 48 hrs by CellTiter 96 assay Growth inhibition of IL3-stimulated mouse BA/F3 cells after 48 hrs by CellTiter 96 assay	[PMID: 23957426]
ECa-109 cell line	IC₅₀	5.01 μM Compound: 8	Antitumor activity against human EC109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antitumor activity against human EC109 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35504209]
HCT-116	IC₅₀	4.6 μM Compound: 47	Inhibition of STAT3 expressed in human HCT116 cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 expressed in human HCT116 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22650325]
Hep 3B2	IC₅₀	>30 μM Compound: 3, cryptotanshinone	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	>30 μM Compound: 3, cryptotanshinone	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	1.36 μM Compound: 3, cryptotanshinone	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HepG2	IC₅₀	29.2 μM Compound: 8	Antitumor activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35504209]
KB 3-1	IC₅₀	6.9 μM Compound: 1	Cytotoxicity against drug-sensitive human KB-3-1 cells after 48 hrs by MTS/PMS assay Cytotoxicity against drug-sensitive human KB-3-1 cells after 48 hrs by MTS/PMS assay	[PMID: 11720520]
KB-V1	IC₅₀	7.5 μM Compound: 1	Cytotoxicity against multidrug-resistant human KBV1 cells after 48 hrs by MTS/PMS assay Cytotoxicity against multidrug-resistant human KBV1 cells after 48 hrs by MTS/PMS assay	[PMID: 11720520]
L02	IC₅₀	>20 μM Compound: CTS	Antiproliferative activity against human L02 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT Antiproliferative activity against human L02 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT	[PMID: 39226127]
MCF-10A	IC₅₀	>20 μM Compound: CTS	Antiproliferative activity against human MCF-10A cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT Antiproliferative activity against human MCF-10A cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT	[PMID: 39226127]
MCF7	ED₅₀	0.41 μg/mL Compound: cryptotanshinone	Dose required for reduction in cell growth of human breast cancer MCF-7 cell line Dose required for reduction in cell growth of human breast cancer MCF-7 cell line	[PMID: 15509181]
MDA-MB-231	ED₅₀	0.16 μg/mL Compound: cryptotanshinone	Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line	[PMID: 15509181]
MDA-MB-231	IC₅₀	>20 μM Compound: CTS	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT	[PMID: 39226127]
MDA-MB-468	IC₅₀	>20 μM Compound: CTS	Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability incubated for 48 hrs measured after additional incubation with MTT	[PMID: 39226127]
MIA PaCa-2	IC₅₀	5.8 μM Compound: 14	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
PBMC	IC₅₀	37.4 μM Compound: 1	Inhibition of phytohemagglutininin A-stimulated human PBMC proliferation assessed as decrease in [14C]thymidine incorporation Inhibition of phytohemagglutininin A-stimulated human PBMC proliferation assessed as decrease in [14C]thymidine incorporation	[PMID: 11720520]
Vero C1008	CC₅₀	>300 μM Compound: 28	Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay	[PMID: 35620927]

In Vitro

Cryptotanshinone significantly inhibits STAT3-dependent luciferase activity, the STAT3 Tyr705 phosphorylation and the dimerization of STAT3, compared to tanshinone IIA which exhibits no activity. Cryptotanshinone (7 μM) dramatically blocks STAT3 Tyr705 phosphorylation but not STAT3 Ser727 phosphorylation in DU145 cells, and significantly inhibits JAK2 phosphorylation with IC₅₀ of appr 5 μM without affecting the phosphorylation of upstream kinases c-Src and EGFR, suggesting the inhibition of STAT3 Tyr705 phosphorylation might due to a direct mechanism probably by binding to the SH2 domain of STAT3. Cryptotanshinone significantly inhibits the proliferation of DU145 prostate cancer cells harboring constitutively active STAT3 with GI₅₀ of 7 μM by blocking STAT3 activity, which leads to the down-regulation of cyclin D1, Bcl-xL, and survivin, subsequently the accumulation in the G0-G1 phase. Cryptotanshinone exhibits less growth inhibitory effect on PC3, LNCaP and MDA-MB-468 cells^[1]. Cryptotanshinone significantly attenuates the in vitro hormonal effects of DEX on ovaries, as indicated by a significant decrease in T and an increase in P levels in the culture medium. Cryptotanshinone significantly increases the levels of phosphorylated AKT2 and GSK3β in the DEX-treated ovaries^[2]. Cotreatment with imatinib and Cryptotanshinone shows a significant synergistic killing effect in both imatinib sensitive and resistant CML cell lines, as well as primary CML cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cryptotanshinone reverses the ovarian IR and significantly increases 2-deoxy-D-[1,2-³H]-glucose uptake in all examined tissues from the DEX-treated mice. Cryptotanshinone significantly reduces the ovulation rate and plasma E2 and P levels^[2]. Cryptotanshinone administration significantly reduces the body weight and food intake of ob/ob mice (C57BL/6J-Lepob) and diet-induced obese (DIO) mice in a dose-dependent manner. Cryptotanshinone causes noticeably less fat in the adipose tissues, significant reductions of serum triglycerides and cholesterol levels, and 2.5- to 3-fold higher AMPK activity of the skeletal muscles than in the control mice. Oral administration of Cryptotanshinone at 600 mg/kg/day produces dramatic reductions in blood glucose levels of ob/ob mice (C57BL/6J-Lepob), db/db mice (C57BL/KsJ-Leprdb), and ZDF rats, which occur after 3 days and persist over the entirety of the monitoring period^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 35825-57-1
Appearance Solid
분자량 296.36
화학식 C₁₉H₂₀O₃
Color Pink to red
SMILES

O=C(C1=C2C=CC3=C1CCCC3(C)C)C(C4=C2OC[C@@H]4C)=O
Synonyms

Cryptotanshinon; Tanshinone c
Structure Classification
- Quinones
- Naphthalene Quinones
Initial Source
- Plants
- Labiatae
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (47)

All WBCell Imaging/StainingIn Vivo Efficacy StudyFlow Cytometry

Sort by:

Journal Impact Factor

Cancer Res

Asialoglycoprotein receptor 1 functions as a tumor suppressor in liver cancer via inhibition of STAT3. [Abstract]

2022 Nov 2;82(21):3987-4000. PMID: 36043912

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Cancer Res. 2022 Nov 2;82(21):3987-4000. [Abstract]

Cryptotanshinone (CTS) (1 μg/mL) treatment effectively rescued the increased ^Tyr705STAT3 expression caused by ASGR1 knockdown in HCCLM3 cells.

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Cancer Res. 2022 Nov 2;82(21):3987-4000. [Abstract]

HCCLM3 cells were injected subcutaneously in 6-week-old nude mice to form xenograft tumors. One week after xenograft tumor formation, mice were intraperitoneally injected with PBS or Cryptotanshinone (CTS) (50 mg/kg, 0.1 mL/10g) every two days. The volume of the xenograft tumor of the mice was measured every two days (means ± SD, unpaired Student t test). ns, nonsignificant.
Nat Commun

IL6 supports long-term expansion of hepatocytes in vitro. [Abstract]

2022 Nov 29;13(1):7345. PMID: 36446858
Autophagy

Organelle contact reorganization drives calcium-dependent autophagy under proteostatic stress. [Abstract]

2026 Jun 6:1-20. PMID: 42152515
Adv Sci (Weinh)

Reshaping Intratumoral Mononuclear Phagocytes with Antibody-Opsonized Immunometabolic Nanoparticles. [Abstract]

2023 Dec;10(34):e2303298. PMID: 37867225
Chem Eng J

2026 Feb 12.
Exp Mol Med

TXNIP: A key protein in the cellular stress response pathway and a potential therapeutic target. [Abstract]

2023 Jul;55(7):1348-1356. PMID: 37394581

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2023 Jul;55(7):1348-1356. [Abstract]

Detection of protein changes in STAT3 activity, FOXM1 and ATG7 levels, induced by icotinib in indicated cells with or without the treatments of IL-6 (10 ng/mL; 24 h) or Cryptotanshinone (CNT) (7 μM; 24 h). The results showed that Cryptotanshinone (CNT) remarkably inhibited the activation of STAT3 and abrogated the levels of FOXM1 and ATG7 during icotinib treatment.

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2023 Jul;55(7):1348-1356. [Abstract]

Detection of protein changes in STAT3 activity, autophagic flux with the mRFP-GFP-LC3 reporter, induced by icotinib in indicated cells with or without the treatments of IL-6 (10 ng/mL; 24 h) or Cryptotanshinone (CTN) (7 μM; 24 h).
J Exp Clin Cancer Res

Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib. [Abstract]

2022 Jun 11;41(1):200. PMID: 35690866
Pharmacol Res

Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. [Abstract]

2021 Jan;163:105232. PMID: 33027716
Cancer Lett

Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression. [Abstract]

2024 Jul 1:593:216963. PMID: 38768682
Cell Death Dis

The autophagy-independent role of BECN1 in colorectal cancer metastasis through regulating STAT3 signaling pathway activation. [Abstract]

2020 May 1;11(5):304. PMID: 32358527
Phytomedicine

Cryptotanshinone attenuates lactate-induced nucleus pulposus cells injury by modulating the STAT3/SIRT3 signaling axis. [Abstract]

2025 Sep:145:157021. PMID: 40609385
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
OncoImmunology

TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth. [Abstract]

2022 Feb 1;11(1):2032918. PMID: 35127254
J Pineal Res

MicroRNA-7 inhibits melatonin synthesis by acting as a linking molecule between leptin and norepinephrine signaling pathways in pig pineal gland. [Abstract]

2019 Apr;66(3):e12552. PMID: 30618087
J Ethnopharmacol

Enhancement of endometrial receptivity by Bushen Zhuyun Decoction via cryptotanshinone-mediated TRIM28 induction and HIF-1α suppression. [Abstract]

2025 May 29:119943. PMID: 40449692
World J Gastroenterol

Cryptotanshinone induces apoptosis of activated hepatic stellate cells via modulating endoplasmic reticulum stress. [Abstract]

2023 May 7;29(17):2616-2627. PMID: 37213406
Commun Biol

Visible light accelerates skin wound healing and alleviates scar formation in mice by adjusting STAT3 signaling. [Abstract]

2024 Oct 5;7(1):1266. PMID: 39367154
Mech Ageing Dev

Role and mechanism of TXNIP in ageing-related renal fibrosis. [Abstract]

2021 Jun:196:111475. PMID: 33781783
Life Sci

Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. [Abstract]

2020 Apr 1;246:117366. PMID: 32001266
Front Pharmacol

Cryptotanshinone affects HFL-1 cells proliferation by inhibiting cytokines secretion in RAW264.7 cells and ameliorates inflammation and fibrosis in newborn rats with hyperoxia induced lung injury. [Abstract]

2023 Jul 25:14:1192370. PMID: 37560477
Int Immunopharmacol

Cryptotanshinone inhibits osteoclast differentiation by targeting LCP1 to suppress diabetic osteoporosis. [Abstract]

2025 Dec 26:170:116115. PMID: 41455366
Eur J Pharmacol

Cryptotanshinone modulates proliferation, apoptosis, and fibrosis through inhibiting AR and EGFR/STAT3 axis to ameliorate benign prostatic hyperplasia progression. [Abstract]

2023 Jan 5:938:175434. PMID: 36462735

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jan 5:938:175434. [Abstract]

Cryptotanshinone (CTS; 10, 20 μМ; 24 h) promotes apoptosis of BPH-1 (fig A) and WPMY-1 (fig B) cells.

Cryptotanshinone purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jan 5:938:175434. [Abstract]

Cryptotanshinone (CTS; 0, 10, 20 μМ; 24 h) significantly decreases the expression of Col-I and (when at 20 μМ) Col-III, α-SMA in WPMY-1 cells.
ACS Omega

Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification. [Abstract]

2025 Apr 29;10(18):19019-19032. PMID: 40385224
Front Cell Dev Biol

Irradiation Haematopoiesis Recovery Orchestrated by IL-12/IL-12Rβ1/TYK2/STAT3-Initiated Osteogenic Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells. [Abstract]

2021 Sep 3:9:729293. PMID: 34540843
J Cell Mol Med

Tetrandrine, an agonist of aryl hydrocarbon receptor, reciprocally modulates the activities of STAT3 and STAT5 to suppress Th17 cell differentiation. [Abstract]

2017 Sep;21(9):2172-2183. PMID: 28332288
Sci Rep

Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells. [Abstract]

2023 Dec 9;13(1):21835. PMID: 38071213
Aging (Albany NY)

Attenuation of doxorubicin-induced cardiotoxicity by cryptotanshinone detected through association analysis of transcriptomic profiling and KEGG pathway. [Abstract]

2020 May 26;12(10):9585-9603. PMID: 32457254
Sci Rep

Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. [Abstract]

2016 Dec 6;6:38408. PMID: 27922075
J Virol

Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin β3 Levels and Is Dependent on STAT3. [Abstract]

2020 Feb 14;94(5):e01384-19. PMID: 31801855
Cell Signal

Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis. [Abstract]

2020 Feb;66:109445. PMID: 31730896
PLoS Genet

Systems biology of tissue-specific response to Anaplasma phagocytophilum reveals differentiated apoptosis in the tick vector Ixodes scapularis. [Abstract]

2015 Mar 27;11(3):e1005120. PMID: 25815810
Exp Cell Res

Interleukin 10 inhibits oxidative stress-induced autophagosome formation in hepatic stellate cells by activating the mTOR-STAT3 pathway. [Abstract]

2022 Feb 15;411(2):113001. PMID: 34973945
Mol Med Rep

Cryptotanshinone interferes with chondrocyte apoptosis in osteoarthritis by inhibiting the expression of miR‑574‑5p. [Abstract]

2021 Jun;23(6):424. PMID: 33878859
Exp Cell Res

HPRT promotes proliferation and metastasis in head and neck squamous cell carcinoma through direct interaction with STAT3. [Abstract]

2021 Feb 1;399(1):112424. PMID: 33340493
Int J Chron Obstruct Pulmon Dis

Cryptotanshinone Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ in Chronic Obstructive Pulmonary Disease. [Abstract]

2023 May 6:18:797-809. PMID: 37180749
Life Sci Alliance

Tanshinone functions as a coenzyme that confers gain of function of NQO1 to suppress ferroptosis. [Abstract]

2022 Nov 1;6(1):e202201667. PMID: 36319062
J Radiat Res Appl Sci

2026 Mar 2.
Cell Biochem Biophys

Downregulation of N-myc Interactor Promotes Cervical Cancer Cells Growth by Activating Stat3 Signaling. [Abstract]

2021 Mar;79(1):103-111. PMID: 33106998
Biomed Res Int

Radix Salvia miltiorrhiza for Ankylosing Spondylitis: Determining Potential Inflammatory Molecular Targets and Mechanism Using Network Pharmacology. [Abstract]

2022 Sep 13;2022:3816258. PMID: 36147634
Biomed Res Int

Network-Based Pharmacology and Bioinformatics Study on the Mechanism of Action of Gujiansan in the Treatment of Steroid-Induced Avascular Necrosis of the Femoral Head. [Abstract]

2022 Jul 23:2022:8080679. PMID: 35915795
Eur J Histochem

Cryptotanshinone alleviates DSS-induced colitis in mouse by regulating the balance of Treg/Th17 cells and M1 macrophage activation. [Abstract]

2026 Jan 26;70(1). PMID: 41711159
Am J Transl Res

pSTAT3 Y705 is a prognostic biomarker identified from time-series gene expression profiles of a chemically induced mouse model of hepatocellular carcinoma. [Abstract]

2020 Apr 15;12(4):1443-1458. PMID: 32355553
Am J Transl Res

TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner. [Abstract]

2016 Sep 15;8(9):3848-3860. PMID: 27725864
Acta Mater Med

2025 Mar 24.
Asian Pac J Cancer Prev

LIN28B Enhanced STAT3 Signaling Regulates Inflammatory Response and Chemotherapeutic Resistance in Cholangiocytes. [Abstract]

2021 Nov 1;22(11):3671-3678. PMID: 34837926
University of North Carolina

2021.
Research Square Print

2020 Jan.

용액&용해도

In Vitro:

DMSO : 5 mg/mL (16.87 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3743 mL

16.8714 mL

33.7427 mL

5 mM

0.6749 mL

3.3743 mL

6.7485 mL

10 mM

0.3374 mL

1.6871 mL

3.3743 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.83 mg/mL (2.80 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.83 mg/mL (2.80 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.83 mg/mL (2.80 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 8 mg/mL (26.99 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

HCT-116 cells are transiently transfected with reporter plasmid having the STAT3-binding element for regulating luciferase assay. Cells are treated with Cryptotanshinone for 24 hours at a concentration range of 0.2 to 50 μM. After treatment, cells are harvested in 20 μL of passive lysis buffer and luciferase activity is evaluated by the Dual Luciferase Reporter Assay kit on Wallac Victor2. The concentration of Cryptotanshinone that inhibits the luciferase activity by 50% represents IC₅₀ value.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

The MTT assay is used for the assessment of cell growth inhibition as described previously. Cells are seeded at a density of 8000 cells per well in 96-well plates in RPMI-1640 containing 10% FBS. Different concentrations of imatinib and CPT are added and incubated for another 24 h. Then, 20 μL of MTT are added into each well and the absorbance at 570 nm is measured on an enzyme linked immunosorbent assay (ELISA) plate reader. The coefficient of drug interaction (CDI) between imatinib and CPT is determined according to a previous study. The calculated method is as follows: CDI/AB/(A × B). According to the absorbance of each group, AB is the ratio of the combination group to the control group; A or B is the ratio of the single agent group to the control group. CDI < 1 indicates a synergistic effect; CDI=1 indicates an additive effect; CDI > 1 indicates an antagonistic effect. In the combination treatment group, the concentrations of CPT are arbitrarily designated according to the 50% inhibitory concentration (IC₅₀) value. Then, the cell viabilities are determined after treatment with different concentrations of imatinib plus CPT (constant CPT concentration for one cell type). Finally, the combination IC₅₀ values of imatinib are calculated, and are represented in Table I. The primary CML cells CP1 to CP3 are isolated from patients in chronic phase, while BC1 and BC2 are isolated from patients in blast crisis. Three independent sets of experiments are performed. The IC₅₀ values are presented as the mean±standard deviation (SD).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shin DS, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009 Jan 1;69(1):193-202. [Content Brief]

[2]. Huang Y, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 2014 Aug;102(2):589-596.e4. [Content Brief]

[3]. Ge Y, et al. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells. Leuk Lymphoma. 2014 Jun 25:1-9. [Content Brief]

[4]. Kim EJ, et al. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol. 2007 Jul;72(1):62-72. Epub 2007 Apr 11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3743 mL	16.8714 mL	33.7427 mL	84.3569 mL
	5 mM	0.6749 mL	3.3743 mL	6.7485 mL	16.8714 mL
	10 mM	0.3374 mL	1.6871 mL	3.3743 mL	8.4357 mL
	15 mM	0.2250 mL	1.1248 mL	2.2495 mL	5.6238 mL

Keywords

Cryptotanshinone

47 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Cryptotanshinone

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Cysteine Targeted Covalent Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Quinones Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cryptotanshinone

All STAT Isoforms

Biological Activity

Chemical Information

Publications (47)

용액&용해도

Protocol

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Cryptotanshinone Related Classifications

Cat. No.: HY-N0174